Gilead Sciences CFO Andrew Dickinson Executes Pre-Planned $468K Share Sale
GILEAD SCIENCES, INC.
Subscribe to track GILD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📢 Insider Transaction Report: GILD Insider: Dickinson Andrew D (Chief Financial Officer) Action: Sold 3,000 shares of Common Stock at $156.22 Total Value: $468,660.00 Shares Remaining: 161,096 Significance: Low (Executed under Rule 10b5-1 plan adopted Aug 29, 2024)
Comprehensive Analysis
Transaction Summary
On October 15, 2026, Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. ($GILD), executed an open-market sale of 3,000 shares of Gilead common stock at a price of $156.22 per share. The transaction generated total proceeds of approximately $468,660.
Key Highlights
- 10b5-1 Trading Plan: The disposition was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
- Remaining Holdings: Following the sale, Mr. Dickinson directly retains 161,096 shares of Gilead Sciences common stock.
- Impact on Stake: The 3,000 shares sold represent roughly 1.8% of his direct holdings prior to the transaction.
Market Impact & Significance
The trading significance is assessed as Low. Because the sale was executed under an established Rule 10b5-1 trading plan and represents only a minor fraction of the CFO's overall direct equity stake, it reflects routine financial planning rather than a directional view on company performance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.